Seroatlas · Human Serome Atlas

AGBL1

Cytosolic carboxypeptidase 4

Also known as: CBPC4_HUMAN, CCP4, FLJ32310

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q96MI9
Gene
AGBL1
Ensembl
ENSG00000273540
Chromosome
15
Canonical length
1112 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins

OverviewNCBI Gene

Polyglutamylation is a reversible posttranslational modification catalyzed by polyglutamylases that results in the addition of glutamate side chains on the modified protein. This gene encodes a glutamate decarboxylase that catalyzes the deglutamylation of polyglutamylated proteins. Mutations in this gene result in dominant late-onset Fuchs corneal dystrophy. [provided by RefSeq, Nov 2013]

Canonical amino-acid sequenceUniProt

1112 residues, UniProt reviewed canonical sequence.

>Q96MI9|AGBL1
     1  MAEQEASGLQ VLLHTLQSSS DKESILTILK VLGDLLSVGT DRRIHYMISK GGSEALLQTL
    61  VDTARTAPPD YDILLPLFRL LAKVGLRDKK IGRKALELEA LDVTLILARK NLSHGQNLLH
   121  CLWALRVFAS SVSMGAMLGI NGAMELLFKV ITPYTRKRTQ AIRAATEVLA ALLKSKSNGR
   181  RAVNRGYVTS LLGLHQDWHS HDTANAYVQI RRGLLLCLRH IAALRSGREA FLAAQGMEIL
   241  FSTTQNCLDD KSMEPVISVV LQILRQCYPT SPLPLVTASS AYAFPVPGCI TTEPPHDLPE
   301  EDFEDDGDDE VDKDSDTEDG KVEDDDLETD VNKLSSKPGL DRPEEELMQY EVMCLELSYS
   361  FEELQSKLGD DLNSEKTQYA NHHHIPAAAS SKQHCYSKDQ SSCGQEREYA VQTSLLCRVK
   421  TGRSTVHLGS KKNPGVNLYQ NVQSNSLRRD SSESEIPDIQ ASPKADAWDV DAIFCPRMSA
   481  SFSNSTRTRE VVKVIDKLLQ THLKRVPFHD PYLYMAKARR TSSVVDFKMM AFPDVWGHCP
   541  PPTTQPMLER KCGVQRIRIF EDIRRLIQPS DVINKVVFSL DEPWPLQDNA SNCLRFFSKF
   601  ESGNLRKAIQ VREFEYDLLV NADVNSTQHQ QWFYFKVSGM QAAIPYHFNI INCEKPNSQF
   661  NYGMQPTLYS VKEALLGKPT WIRTGHEICY YKNHYRQSTA VAGGASGKCY YTLTFAVTFP
   721  HSEDVCYLAY HYPYTYTALM THLDILEKSV NLKEVYFRQD VLCQTLGGNP CPLVTITAMP
   781  ESNSDEHLEQ FRHRPYQVIT ARVHPGESNA SWVMKGTLEF LVSSDPVARL LRENFIFKII
   841  PMLNPDGVIN GNHRCSLSGE DLNRQWLSPS AHLQPTIYHA KGLLYHLSSI GRSPVVFCDF
   901  HGHSQKKNVF LYGCSIKETL WQAACTVGTS TILEEVNYRT LPKILDKLAP AFTMSSCSFL
   961  VEKSRASTAR VVVWREMGVS RSYTMESSYC GCNQGPYQCT QRLLERTKNE RAHPVDGLQG
  1021  LQFGTRELEE MGAMFCLGLL ILELKSASCS HQLLAQAATL LSAEEDALDQ HLQRLKSSNF
  1081  LPKHIWFAYH FFAITNFFKM NLLLHVSPVC DT

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AGBL1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.29
Highest tissue expression
22 nTPM

Expression across tissuesHPA

Tissue

  • tongue: 22 nTPM
  • skeletal muscle: 7 nTPM
  • basal ganglia: 1.5 nTPM
  • lung: 0.6 nTPM
  • esophagus: 0.5 nTPM
  • cerebral cortex: 0.4 nTPM

Single-cell type

  • myonuclei: 2,288 nCPM
  • ependymal cells: 1,755 nCPM
  • thymic myoid cells: 969 nCPM
  • alveolar cells type 2: 446 nCPM
  • gonadotrophs: 213 nCPM
  • transitional alveolar cells: 169 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • basal ganglia: 3.8 nTPM
  • medulla oblongata: 3 nTPM
  • cerebral cortex: 2.9 nTPM
  • spinal cord: 2.8 nTPM
  • midbrain: 2.5 nTPM
  • amygdala: 1.9 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about AGBL1.

Disease | AllUniProt

Conditions AGBL1 is implicated in, by any mechanism.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.14
gnomAD pLI
0
gnomAD missense Z
-2.23
DepMap mean gene effect
0.04
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of AGBL1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AGBL1 as an antibody target. Whether an autoantibody or antibody against AGBL1 could matter depends on whether native AGBL1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AGBL1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label AGBL1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/AGBL1. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...